ClinVar Miner

Submissions for variant NM_002524.5(NRAS):c.35G>C (p.Gly12Ala)

dbSNP: rs121913237
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 13
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Hospital of the University of Pennsylvania, Center for Personalized Diagnostics RCV000203450 SCV000258463 pathogenic Myelodysplastic syndrome progressed to acute myeloid leukemia 2016-01-08 criteria provided, single submitter clinical testing Activating mutation
GeneDx RCV000380895 SCV000330301 pathogenic not provided 2017-02-01 criteria provided, single submitter clinical testing The G12A missense varant in the NRAS gene has been reported previously as a somatic mutation in association with several different types of cancer and primarily affected haematopoietic and lymphoid tissues (Catalogue of Somatic Mutations in Cancer; ClinVar SCV000258463.2: Landrum et al. 2014). G12A was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. G12A is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. The glycine codons 12 and 13 of RAS proteins within the RAS/MAPK pathway are functionally important for GDP/GTP binding and are considered hot spots" for pathogenic variants (Wey et al. 2013; Gripp et al. 2012). Missense variants in the same codon (G12S) and in a nearby residue (G13D) have been reported in the Human Gene Mutation Database in association with NRAS-related disorders (Stenson et al., 2014), supporting the functional importance of this region of the protein."
Invitae RCV001324275 SCV001515224 likely pathogenic RASopathy 2022-11-29 criteria provided, single submitter clinical testing ClinVar contains an entry for this variant (Variation ID: 219097). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Gly12 amino acid residue in NRAS. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 28098151, 28594414). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt NRAS protein function. This variant has not been reported in the literature in individuals affected with NRAS-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glycine, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 12 of the NRAS protein (p.Gly12Ala).
Genome Diagnostics Laboratory, The Hospital for Sick Children RCV001813426 SCV002060960 pathogenic Noonan syndrome and Noonan-related syndrome 2018-08-01 criteria provided, single submitter clinical testing
Database of Curated Mutations (DoCM) RCV000434113 SCV000503709 pathogenic Melanoma 2014-10-02 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000444670 SCV000503710 pathogenic Neoplasm of the large intestine 2016-05-31 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000427550 SCV000503711 pathogenic Non-small cell lung carcinoma 2014-10-02 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000433455 SCV000503712 likely pathogenic Gastric adenocarcinoma 2016-05-31 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000444591 SCV000503713 likely pathogenic Malignant melanoma of skin 2016-05-31 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000426950 SCV000503714 likely pathogenic Acute myeloid leukemia 2016-05-31 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000437165 SCV000503715 likely pathogenic Malignant neoplasm of body of uterus 2016-05-31 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000418647 SCV000503716 likely pathogenic Multiple myeloma 2016-05-31 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000425963 SCV000503717 likely pathogenic Myelodysplastic syndrome 2016-05-31 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.